WhizAI, which touts itself as the first and only purpose-built cognitive insights platform for the life sciences, secured $4 million in seed funding.Subscribe to theCrunchbase DailyThe Somerset, New Jersey-based company’s platform uses artificial intelligence, machine learning and scalability to learn the language and data of life sciences to provide insights to customers about business questions.“One thing we kept seeing was apps geared toward dashboards, but those are for people who are already tech savvy,” WhizAI co-founder and CEO Rohit Vashisht told Crunchbase News. “There are people who need data, but can’t use those products, so we created one. We focused first on the sales side of the pharmaceutical business. They can use SMS to text a question, and WhizAI pulls the data and puts it into a chart.”Healthy Ventures led the round, with participation from Bling Capital, Firebolt Ventures and existing investors. WhizAI previously raised $2.5 million in other seed rounds and other investments a few years ago, according to Crunchbase data. With this new investment, the company has raised more than $6.5 million since being founded in 2017.As part of the financing, Healthy Ventures’ founder and general partner Anya Schiess will join WhizAI’s board of directors.The new funding will be used for product development, new hires and to increase sales and marketing, Vashisht said.In terms of growth, WhizAI has 43 employees right now at its offices in New Jersey, India and Ukraine, having grown from 19 three months ago. By the end of the year, Vashisht expects that number to be about 70. Revenue has grown five times between 2019 and 2020, and he anticipates the same next year.“We are seeing very rapid growth, especially now that we have signed a major contract with a global pharmaceutical company that will have thousands of users,” he said. “We also plan to have a small office in Europe and will go live in 26 countries.”Illustration: Li-Anne Dias
People also viewed
2022 PMSA Fall Symposium
2022 PMSA FALL SYMPOSIUM October 27 – 28, 2022 Caesars Palace, Las Vegas, Nevada
Customer Centricity and Digital Experiences which are Redefining Pharma
It is no secret that the pharmaceutical industry has historically flourished from blockbuster products with substantial brand equity, favorable pricing
Awash in Data, Yet Starving for Insights? Transform Life Sciences Commercial Teams with AI-Powered Analytics
Personalized communication is something the HCPs have come to expect. To do that, pharma sales reps need to know their customers well. In order to know the customer well, they need data. Enterprise pharma companies, however, have many data resources and lots of data at their disposal. In fact, there is a data explosion. So what do you do?
Augmented Analytics is “On the Rise” on Gartner’s 2022 Hype Cycle for Life Science Commercial Operations
The Gartner® 2022 Hype Cycle™ for Life Science Commercial Operations introduces a new category, Augmented Analytics, this year. WhizAI is listed as a sample vendor in the Augmented Analytics category in this Hype Cycle. This summary report covers the following highlights.
Where Gartner Positions Natural Language Query on the Hype Cycle and What It Means for Life Sciences
Gartner® 2022 Hype Cycle™ for Natural Language Technologies (NLT) shows natural language query (NLQ) adoption is accelerating. WhizAI was recently recognized as a Sample Vendor in the Natural Language Query category in several Gartner Hype Cycles:
AI Powered Business Intelligence for Life Science Leaders: Save Time, Drive Adoption and Scale Faster
Today’s commercial teams must pinpoint top opportunities in markets across the country—or across the world—based on regulations, drug trials, market activity, competitors, insurance records, HCP preferences and affiliations, much more data than is humanly possible to manage.